Bartonella: emerging pathogen or emerging awareness?  by Mogollon-Pasapera, Elin et al.
International Journal of Infectious Diseases (2009) 13, 3—8PERSPECTIVE
Bartonella: emerging pathogen or emerging
awareness?
Elin Mogollon-Pasapera, Laszlo Otvos Jr, Antonio Giordano, Marco Cassone *
http://intl.elsevierhealth.com/journals/ijidSbarro Health Research Organization, College of Science and Technology, Temple University,
BioLifeScience Building suite 419, 1900 N 12th Street, 19122 Philadelphia, PA, USA
Received 17 October 2007; received in revised form 26 January 2008; accepted 14 April 2008
Corresponding Editor: William Cameron, Ottawa, CanadaKEYWORDS
Bartonella;
Carrion’s disease;
Epidemiology;
Cat-scratch disease;
Therapy
Summary The number of known Bartonella species is rapidly growing. Some of them are
responsible for distinct infectious diseases and show different prevalence and antibiotic suscept-
ibility profiles. Not only have some vectors of Bartonella not been fully characterized, but also
intermediate hosts are actually muchmore numerous and diverse than previously thought. Among
these, dogs differ from cats because they tend to suffer an overt disease similar to humans, thus
providing the base for a useful animal indicator and research model. Among the debilitating
conditions with an unclear impact on the course of these infections, specific conditions (e.g.,
homelessness, alcoholism) have been linked to a much higher prevalence and to high risk of
unfavorable outcome. Due to the limited arsenal of antibiotics effective in vivo on this peculiar
intracellular pathogen, the risk/benefit balance of antibiotic therapy is sometimes difficult to
draw. In this evolving picture, the recent discoveries of new species highlights the importance of
basic molecular biology resources that would bring major public health benefits if available in
endemic areas, and specifically in many areas of Peru and Bolivia.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.The growing impact of Bartonella
Many species of Bartonella have been affecting human life for
centuries. Bartonella quintana, for example, has been
implied as one of the possible causes of the decline of the
Inca Empire.1 The genus is named after Alberto Leonardo
Barton Thompson, who in 1905 discovered Bartonella bacil-
liformis, the causative agent of the Oroya fever (or Carrion’s
disease), a severe febrile illness accompanied by bacteremia,
endocarditis, hemolysis, and circulatory collapse, or by
encephalitis.2 Of the 21 species described, about half are* Corresponding author. Tel.: +1 215 204 4265; fax: +1 215 204 9522.
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Bartonella species are transmitted between the reservoir
and the final mammal host by insects such as fleas, sand flies,
and possibly ticks, by bites or other means (e.g., feces of flea
in cat-scratch disease). The range of vectors involved in the
transmission of the different species of this genus has not
been fully characterized.
From a clinical point of view, Bartonella infections can
range from self-limited to life-threatening, and may present
different course and organ involvement, due to a balance of
host and bacterial factors still not well understood. Our
knowledge in all aspects of Bartonella infections is improving
and many species have been characterized, but more are
discovered each year. Also, some already-known species havePublished by Elsevier Ltd. All rights reserved.
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antibiotic susceptibility profiles. Interesting novelties also
regard the hosts: dogs, for example, have been recently
identified as an important intermediate host for several
species, and in few cases as the definitive host.
Bartonella infections produce a remarkable range of
symptoms, due to chronic or acute infections with variable
pathology. Besides Oroya fever, Bartonella infections cause
trench fever, bacteremia and endocarditis, cat-scratch dis-
ease, bacillary angiomatosis, and other granulomatous infec-
tions involving several organs.3—5
Epidemiology and diagnosis
Besides geographic areas of endemic distribution, for exam-
ple B. bacilliformis in Los Andes in Peru, Bartonella infections
have shown an unexpectedly high prevalence worldwide. As
an example, it was recently made clear that bartonelloses
are common in Europe.6 Specific studies have been con-
ducted for selected categories such as the homeless, drug
users, and veterinarians.7—9 A case report on cat-scratch
disease in a family demonstrated that the infection was
transmitted by the same kitten to four different individuals,
and each presented with different clinical characteristics,
treatment, and evolution.10 A recent report described two
cases of transverse myelitis in patients that were positive for
Bartonella henselae.11 Also, the geographic distribution of
the pathogen may be dependent on temporary or permanent
climatic alterations such as tropical storms, as described for
B. bacilliformis, and possibly global warming.1 These alarm-
ing findings, together with increasing resistance to antimi-
crobial agents, are leading Bartonella to be viewed as
emerging, or reemerging pathogens.12 However, what is
especially new is the interest on the science and public
health side, and the awareness that so much is not yet
understood.
Bacteria from the genus Bartonella are fastidious to grow
in vitro, and the most used diagnostic means are serology and
PCR. Both methods are quick, sensitive, and reliable for
patient management purposes. Whenever possible, addi-
tional downstream analysis should be performed on PCR
amplicons to screen for new species, especially when dealing
with uncommon clinical presentations and settings. The
importance of this approach is underlined by the recent case
report of the isolation of a new proposed Bartonella species,
named Bartonella rochalimae, in an American tourist.13
Clinical presentations
Less than 20 years ago, just a few species of Bartonella were
known: among them B. bacilliformis and B. quintana. With
the discovery, in 1992, that the new species B. henselae
(originally named Rochalimaea henselae) was the etiologic
agent of the mysterious cat-scratch disease,14 worldwide
interest and scientific efforts started to pour in on this genus,
and more than one new species each year has been discov-
ered in the last decade.12,13
The most common bartonellosis is the ‘Oroya fever’, or
Carrion’s disease. This was one of the first human diseases to
be described, given that the millenary civilizations of the
Mochicas, Chimu, and Nazca in Peru represented it in theirceramics. The symptomatic disease presents two phases: an
initial, acute or subacute phase in which the symptoms are
fever, anemia, and jaundice, and then a chronic phase
characterized by the ‘verruga peruana’ (Peruvian wart).
For many years it was not clear that these are two phases
of the same disease, until 1885, when the medical student
and Peruvian hero Daniel Alcides Carrion, inoculated himself
with B. bacilliformis from a patient in the chronic phase of
the disease. He developed the Oroya fever, losing his life to
demonstrate an etiologic link with the ‘verruga peruana’.
Bartonellosis has been identified in various regions of Peru
but is most commonly found in the Andes Valleys between 500
and 3500 meters over sea level, which is the home of the sand
fly Lutzomyia verrucarum, the principal vector of B. bacilli-
formis. More than 26 000 cases of bartonellosis were reported
between 2004 and 2006 by the Peruvian National Institute of
Health. Since the mortality can be high in certain outbreaks,
especially among pediatric patients,1 it can be estimated
that in Peru only, hundreds of people die each year from this
disease, generally due to lack of preventive measures and for
not reporting to a health center to be treated.
Another member of the Bartonella genus is B. quintana, a
microorganism that is transmitted by feces of human louse
into abraded skin or into the conjunctiva. B. quintana is the
agent of trench fever, a bacteremic disease that was
described in 1915 and resulted in about 1 million soldiers
being infected in Europe during World War I. Its symptoms
may include high fever, severe headache, pain in moving the
eyeballs, soreness of the muscles of the legs and back, and
frequently hyperesthesia of the shins. Pathologic manifesta-
tions of endocarditis have been described in some specimens.
Nowadays, B. quintana infection is highly prevalent among
homeless alcoholics, and is also present among veterinarians
in the USA and Europe.7—9
Bartonella henselae is well known for causing cat-scratch
disease, usually characterized by a mild infection that may
be limited to the site of injury, or may present general
systemic symptoms such as fever, headache, fatigue, and
poor appetite. Recently, it has been observed that this
pathogen may enter human erythrocytes, like B. bacillifor-
mis and B. quintana.15 This observation raised some concern
regarding the need of transfusion screening practices. Immu-
nocompromised patients, but also sometimes apparently
healthy subjects, may show severe granulomatous lesions
of internal organs. Patients with AIDS are especially at risk for
bacillary angiomatosis, a disease caused by B. henselae and
B. quintana characterized by the proliferation of blood
vessels. The lesions are found most often in the skin but
may affect almost any organ. The disease may be lethal if not
recognized and treated. In Table 1 we report the pathogenic
Bartonella species described so far, along with the clinical
manifestations of disease they can cause in humans and in
dogs. The complete genomes of B. bacilliformis, B. quintana,
B. henselae, and Bartonella tribocorum have been
sequenced so far (http://www.ncbi.nlm.nih.gov/genomes/
lproks.cgi).
Vectors and reservoirs
DNA of some Bartonella species has been found in several
different vectors. A very recent study, for example, reported
the molecular detection of B. tribocorum and Bartonella
Table 1 Bartonella species infecting humans
Species Year of
description
Place Author Main vectors Main
reservoirs
Main human
diseasesa
Recommended
antibiotics
Dog diseases
B. bacilliformis 1909 Peru Barton Sand fly Human Carrion’s
disease
Acute disease:
ciprofloxacin
(amoxicillin
clavulanate
for children
and pregnant
women), or
chloramphenicol
Chronic disease:
azithromycin
B. quintana 1915 Russia Strong Body louse Human Trench fever Doxycycline Endocarditis
CSD
BA
CA Erythromycinb
Bacteremia Erythromycin
Endocarditis Gentamicin
and
doxycycline
Septicemia Gentamicin
and
doxycycline
B. henselae 1992 USA Regnery Cat flea Cat CSD Doxycycline Endocarditis
BA Erythromycinb Granulomatous
hepatitis
CA Erythromycin
Bacteremia Peliosis hepatis
Endocarditis Gentamicin
and
doxycycline
Epistaxis
Septicemia
B. elizabethae 1993 USA Daly Oriental rat
flea, rodent
fleas
Rat Endocarditis Not established Lethargy
Retinitis Anemia
Weight loss
B. grahamii 1995 UK Birtles Wild mice Retinitis Doxycycline
and rifampin
Not diagnosed
in dogs
B. washoensis 1995 USA Regnery Unknown
(flea?)
California
ground
squirrel
Fever Not established Endocarditis
Myocarditis
B. vinsonii
subspecies
berkhoffii
1996 Canada Kordick Unknown
(tick?)
Coyote,
dog
Endocarditis Doxycycline
plus
gentamicin or
a quinolone
Endocarditis
Myocarditis
Arrhythmia
Uveitis
Choroiditis
Splenomegaly
Polyarthritis
Epistaxis
B. clarridgeiae 1996 USA Lawson Cat flea Cat CSD Not established Endocarditis
Lymphocytic
hepatitis
B. alsatica 1999 France Heller Unknown
(flea?)
Rabbit Endocarditis Not established
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Species Year of
description
Place Author Main vectors Main
reservoirs
Main human
diseases a
Recommended
antibiotics
Dog diseases
B. vinsonii
subspecies
arupensis
1999 Canada Welch Unknown
(flea, tick?)
White-
footed
mouse
Bacteremia Not established
B. rochalimae 2007 Peru Eremeeva Unknown
(flea?)
Unknown Bacteremia Not established
a CSD, cat-scratch disease; BA, bacillary angiomatosis; CA, chronic adenopathy.
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pis, Ctenophthalmus pseudagyrtes, and Sternopsylla texa-
nus.16 Furthermore, a single tick can harbor Bartonella (such
as B. vinsonii) together with other pathogens.17 When this is a
concern in the differential diagnosis, amplification and
detection of pathogen DNA should be carried out using
techniques that combine high-throughput and sensitivity,
such as broad-range PCR, which uses primers that target
highly-conserved regions of genes common to all bacteria
(e.g., 16S rDNA), combined with separation techniques such
as temporal temperature gradient gel electrophoresis
(TTGE).18 This also allows the prompt detection of unusual
patterns possibly pointing to new species. Vectors should be
much more addressed as a target for prevention efforts:
altering their environmental niche, as well as enhancing
competition by not receptive peers may be successful stra-
tegies.
Pets represent a large reservoir for infections in humans.19
Cats are the main reservoir for species like B. henselae,
Bartonella clarridgeiae, and Bartonella koehlerae. On the
other hand, dogs can be infected with Bartonella berkhoffii,
B. henselae, B. clarridgeiae, Bartonella washoensis, Barto-
nella elizabethae, and B. quintana, but their role as reser-
voirs is not as well understood as for cats because they tend
to be accidental hosts in non-tropical regions and not the
primary reservoir.20 Rat and coyote can also be intermediate
hosts. Domestic dogs as opposed to cats are excellent animals
to study the pathophysiology of infection in humans because
they manifest similar symptoms and clinical and pathologic
findings.21 This gives a totally different perspective from the
one exemplified by Carrion, who experimented on himself
thinking that bartonellosis could only occur in humans.
Indeed, the dog may be a useful animal indicator and
research model, as well as helping epidemiologic and pre-
vention work. Immunocompromised dogs are more likely to
acquire B. henselae than immunocompetent dogs20 according
to studies on healthy and sick dogs in eastern USA that show
an occurrence of 10% of B. henselae antibodies in healthy
dogs and 27% in sick dogs, similar to what occurs in humans. A
case of cat-scratch disease caused by a domestic dog scratch
has been reported in Taiwan.22
Treatment
Bacteria of the genus Bartonella are often, but not always,
susceptible to many antibiotics when they are grown in vitro,
including penicillin, cephalosporins, aminoglycosides, chlor-
amphenicol, rifampin, and fluoroquinolones amongothers.23—25 Nevertheless, some of these antibiotics may
be ineffective in vivo because of the lack of a bactericidal
effect, or the intracellular localization of the bacteria. For
example, penicillin is not effective against B. henselae. Also,
the emergence of resistance to several antibiotics, including
macrolides and quinolones, has been reported, mainly in B.
bacilliformis.26,27
The general recommendations for the treatment of infec-
tions caused by Bartonella species are reported in Table 1,
but may vary according to the type and stage of disease, age
of the patient, and their immune status. In a limited Peruvian
case series, 14 of 16 (88%) untreated patients with Oroya
fever died, while all the 10 chloramphenicol-treated
patients survived.28 Notably, there is often uncertainty over
which treatment is best for children. For uncomplicated cat-
scratch disease therapy is often not needed, however many
antibiotic treatments like the combination of doxycycline
with rifampin in patients with complicated cat-scratch dis-
ease have been successful. Evaluation of the impact that
immunodeficiency and other debilitating conditions in gen-
eral have on the prevalence, course, and especially therapy
outcomes of Bartonella infections, only started in the most
recent years, and still toomany areas of uncertainty remain.
Due to the limited arsenal of antibiotics effective in vivo on
this peculiar intracellular pathogen, drugs with potential
toxic effects are often used. Thus, the risk/benefit balance
of antibiotic therapy must always be carefully evaluated.
Unfortunately, this is a point for which we do not have
enough clinical data, especially regarding children. Specific
conditions (e.g., homelessness and alcoholism) have been
linked to a much higher prevalence and to high risk of
unfavorable outcome, and thus should prompt treat-
ment.7,29,30 Treatment also needs careful evaluation and
the knowledge of the local epidemiological situation. Anti-
microbial susceptibility testing should be performed when-
ever possible. Not surprisingly, the changing knowledge and
awareness of the impact of bartonellosis, together with
evolving susceptibility to antimicrobial drugs, demands con-
tinuous update, and in some cases a reevaluation ofmanage-
ment strategies, which also imply recent calls for
development of a vaccine.
Vaccines
Although very demanding and expensive to generate, vac-
cines are theoretically the best choice to prevent infections
endemic in areas where an appreciable proportion of the
population has limited access to medical facilities. While a
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in humans is still just a dream, the invasion protein IalB of B.
bacilliformis served as a functional template to select a
candidate Brucella melitensis antigen for a DNA vaccine that
resulted protective in mice.31
Veterinarians are pushing for the development of a cat
vaccine against B. henselae,32 due to recent impressive data
on its prevalence in pets.9 A few preliminary studies
addressed the immunogenicity of some B. henselae antigens
and the cross-reactivity between serotypes.33,34 Attenuation
of B. henselae by serial passages in vitro, a classic method
used with other pathogens, has also been attempted, but
further studies are needed to clarify whether these research
approaches have the potential to lead to the development of
a vaccine.35
Conclusions
The discovery of a new species of Bartonella, presumably
endemic in Peru, in a tourist from a highly developed country
underlines oncemore the usefulness and the urgent need for
increased availability of molecular biology resources, such
as those necessary to investigate pathogens at a genomic
level, in many areas of Peru and Bolivia. Limitation of
resources is indeed one of the reasons why many aspects
concerning to Bartonella infections are not yet specified. For
example, a recommended treatment for children with reti-
nitis, trench fever, chronic bacteremia, and endocardi-
tis,3,36 has not been established. Also, data comparing the
outcome of different treatment regimens during pregnancy,
or even just suggesting one, are scarce. Doubts exist about
the safety of chloramphenicol during pregnancy37 due to
observed abortion or fetal demise in somepregnantwomen.5
As suggested by these results, preventive exams that allow
the detection of Bartonella species in women planning to be
pregnant should be taken into consideration at least in
endemic zones.
While epidemiology, clinic, and diagnostics data are con-
tinuously obtained and updated, a major concern lies in the
increase of the higher-risk population with Bartonella infec-
tions and immunodeficiency. The number of patients diag-
nosed with HIV, cancer, tuberculosis, and many other
debilitating diseases is continuously growing, and we are
just starting to understand how far and in how many ways
Bartonella can affect our health. For this reason, research on
bartonellosis should be better supported in many countries.
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